Altered human CYP3A4 activity caused by antley-bixler syndrome-related variants of NADPH-cytochrome P450 oxidoreductase measured in a robust in vitro system

Drug Metabolism and Disposition

Volumn 40, Issue 4, 2012, Pages 754-760

  Moutinho, Daniela ^a   Marohnic, Christopher C ^b,c   Panda, Satya P ^b   Rueff, José ^a   Masters, Bettie Sue ^b   Kranendonk, Michel ^a  

^a UNIVERSIDADE NOVA DE LISBOA   (Portugal)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 3A4; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE DEHYDROGENASE;

ANTLEY BIXLER SYNDROME; ARTICLE; BIOTRANSFORMATION; CATALYSIS; CONTROLLED STUDY; DEBENZYLATION; DENSITOMETRY; ENZYME ACTIVITY; GENETIC VARIABILITY; HUMAN; HUMAN TISSUE; IN VITRO STUDY; LIVER MICROSOME; NUCLEOTIDE SEQUENCE; PHARMACOGENETICS; PRIORITY JOURNAL; STOICHIOMETRY;

ANTLEY-BIXLER SYNDROME PHENOTYPE; BIOTRANSFORMATION; CATALYSIS; CELL MEMBRANE; CYTOCHROME P-450 CYP3A; ESCHERICHIA COLI; FLUORESCEINS; GENETIC VARIATION; HUMANS; MICROSOMES, LIVER; MUTATION; NADPH-FERRIHEMOPROTEIN REDUCTASE; PLASMIDS; SUBSTRATE SPECIFICITY;

MAMMALIA;

EID: 84858412533     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.111.042820     Document Type: Article

References (41)

1. Agrawal V, Choi JH, Giacomini KM, and Miller WL (2010) Substrate-specific modulation of CYP3A4 activity by genetic variants of cytochrome P450 oxidoreductase. Pharmacogenet Genomics 20:611-618.
2. Agrawal V, Huang N, and Miller WL (2008) Pharmacogenetics of P450 oxidoreductase: effect of sequence variants on activities of CYP1A2 and CYP2C19. Pharmacogenet Genomics 18:569-576.
3. Aigrain L, Pompon D, Moréra S, and Truan G (2009) Structure of the open conformation of a functional chimeric NADPH cytochrome P450 reductase. EMBO Rep 10:742-747.
4. Antley R and Bixler D (1975) Trapezoidocephaly, midfacial hypoplasia and cartilage abnormalities with multiple synostoses and skeletal fractures. Birth Defects Orig Artic Ser 11:397-401.
5. Arlt W, Walker EA, Draper N, Ivison HE, Ride JP, Hammer F, Chalder SM, Borucka-Mankiewicz M, Hauffa BP, Malunowicz EM, et al. (2004) Congenital adrenal hyperplasia caused by mutant P450 oxidoreductase and human androgen synthesis: analytical study. Lancet 363:2128-2135. (Pubitemid 38844154)
6. Black SD and Coon MJ (1982) Structural features of liver microsomal NADPH-cytochrome P-450 reductase. Hydrophobic domain, hydrophilic domain, and connecting region. J Biol Chem 257:5929-5938.
7. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254.
8. Busby WF Jr, Ackermann JM, and Crespi CL (1999) Effect of methanol, ethanol, dimethyl sulfoxide, and acetonitrile on in vitro activities of cDNA-expressed human cytochromes P-450. Drug Metab Dispos 27:246-249. (Pubitemid 29072079)
9. Christensen H, Hestad AL, Molden E, and Mathiesen L (2011) CYP3A5-mediated metabolism of midazolam in recombinant systems is highly sensitive to NADPH-cytochrome P450 reductase activity. Xenobiotica 41:1-5.
10. Dhir V, Ivison HE, Krone N, Shackleton CH, Doherty AJ, Stewart PM, and Arlt W (2007) Differential inhibition of CYP17A1 and CYP21A2 activities by the P450 oxidoreductase mutant A287P. Mol Endocrinol 21:1958-1968. (Pubitemid 47173803)
11. Duarte MP, Palma BB, Laires A, Oliveira JS, Rueff J, and Kranendonk M (2005) Escherichia coli BTC, a human cytochrome P450 competent tester strain with a high sensitivity towards alkylating agents: involvement of alkyltransferases in the repair of DNA damage induced by aromatic amines. Mutagenesis 20:199-208. (Pubitemid 40732850)
12. Ellis J, Gutierrez A, Barsukov IL, Huang WC, Grossmann JG, and Roberts GC (2009) Domain motion in cytochrome P450 reductase: conformational equilibria revealed by NMR and small-angle x-ray scattering. J Biol Chem 284:36628-36637.
13. Emoto C, Murayama N, and Yamazaki H (2008) Effects of enzyme sources on midazolam 1′-hydroxylation activity catalyzed by recombinant cytochrome P450 3A4 in combination with NADPH-cytochrome P450 reductase. Drug Metab Lett 2:190-192.
14. Evans WE and McLeod HL (2003) Pharmacogenomics - drug disposition, drug targets, and side effects. N Engl J Med 348:538-549. (Pubitemid 36159890)
15. Flück CE, Mullis PE, and Pandey AV (2010) Reduction in hepatic drug metabolizing CYP3A4 activities caused by P450 oxidoreductase mutations identified in patients with disordered steroid metabolism. Biochem Biophys Res Commun 401:149-153.
16. Fukami M, Horikawa R, Nagai T, Tanaka T, Naiki Y, Sato N, Okuyama T, Nakai H, Soneda S, Tachibana K, et al. (2005) Cytochrome P450 oxidoreductase gene mutations and Antley-Bixler syndrome with abnormal genitalia and/or impaired steroidogenesis: molecular and clinical studies in 10 patients. J Clin Endocrinol Metab 90:414-426. (Pubitemid 40116690)
17. Ghosal A, Hapangama N, Yuan Y, Lu X, Horne D, Patrick JE, and Zbaida S (2003) Rapid determination of enzyme activities of recombinant human cytochromes P450, human liver microsomes and hepatocytes. Biopharm Drug Dispos 24:375-384. (Pubitemid 38072098)
18. Gomes AM, Winter S, Klein K, Turpeinen M, Schaeffeler E, Schwab M, and Zanger UM (2009) Pharmacogenomics of human liver cytochrome P450 oxidoreductase: multifactorial analysis and impact on microsomal drug oxidation. Pharmacogenomics 10:579-599.
19. Guengerich FP (2005) Human cytochrome P450 enzymes, in Cytochrome P450: Structure, Mechanism and Biochemistry (Ortiz de Montellano PR ed) pp 377-530, Plenum Publishers, New York.
20. Guengerich FP, Martin MV, Sohl CD, and Cheng Q (2009) Measurement of cytochrome P450 and NADPH-cytochrome P450 reductase. Nat Protoc 4:1245-1251.
21. Hamdane D, Xia C, Im SC, Zhang H, Kim JJ, and Waskell L (2009) Structure and function of an NADPH-cytochrome P450 oxidoreductase in an open conformation capable of reducing cytochrome P450. J Biol Chem 284:11374-11384.
22. Hart SN, Wang S, Nakamoto K, Wesselman C, Li Y, and Zhong XB (2008) Genetic polymorphisms in cytochrome P450 oxidoreductase influence microsomal P450-catalyzed drug metabolism. Pharmacogenet Genomics 18:11-24. (Pubitemid 351161645)
23. Huang N, Pandey AV, Agrawal V, Reardon W, Lapunzina PD, Mowat D, Jabs EW, Van Vliet G, Sack J, Flück CE, et al. (2005) Diversity and function of mutations in p450 oxidoreductase in patients with Antley-Bixler syndrome and disordered steroidogenesis. Am J Hum Genet 76:729-749. (Pubitemid 40563096)
24. Kranendonk M, Fisher CW, Roda R, Carreira F, Theisen P, Laires A, Rueff J, Vermeulen NP, and Estabrook RW (1999) Escherichia coli MTC, a NADPH cytochrome P450 reductase competent mutagenicity tester strain for the expression of human cytochrome P450: comparison of three types of expression systems. Mutat Res 439:287-300. (Pubitemid 29094821)
25. Kranendonk M, Marohnic CC, Panda SP, Duarte MP, Oliveira JS, Masters BS, and Rueff J (2008) Impairment of human CYP1A2-mediated xenobiotic metabolism by Antley-Bixler syndrome variants of cytochrome P450 oxidoreductase. Arch Biochem Biophys 475:93-99.
26. Kranendonk M, Mesquita P, Laires A, Vermeulen NP, and Rueff J (1998) Expression of human cytochrome P450 1A2 in Escherichia coli: a system for biotransformation and genotoxicity studies of chemical carcinogens. Mutagenesis 13:263-269. (Pubitemid 28243160)
27. Marohnic CC, Huber WJ III, Connick JP, Reed JR, McCammon K, Panda SP, Martásek P, Backes WL, and Masters BS (2011) Mutations of human cytochrome P450 reductase differentially modulate heme oxygenase-1 activity and oligomerization. Arch Biochem Biophys 513:42-50.
28. Marohnic CC, Panda SP, Martásek P, and Masters BS (2006) Diminished FAD binding in the Y459H and V492E Antley-Bixler syndrome mutants of human cytochrome P450 reductase. J Biol Chem 281:35975-35982. (Pubitemid 46041329)
29. Marohnic CC, Panda SP, McCammon K, Rueff J, Masters BS, and KranendonkM(2010) Human cytochrome P450 oxidoreductase deficiency caused by the Y181D mutation: molecular consequences and rescue of defect. Drug Metab Dispos 38:332-340.
30. Paine MF, Khalighi M, Fisher JM, Shen DD, Kunze KL, Marsh CL, Perkins JD, and Thummel KE (1997) Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism. J Pharmacol Exp Ther 283:1552-1562. (Pubitemid 28016533)
31. Pandey AV, Kempná P, Hofer G, Mullis PE, and Flück CE (2007) Modulation of human CYP19A1 activity by mutant NADPH P450 oxidoreductase. Mol Endocrinol 21:2579-2595. (Pubitemid 47529367)
32. Parikh A, Gillam EM, and Guengerich FP (1997) Drug metabolism by Escherichia coli expressing human cytochromes P450. Nat Biotechnol 15:784-788. (Pubitemid 27329483)
33. Porter TD, Beck TW, and Kasper CB (1990) NADPH-cytochrome P-450 oxidoreductase gene organization correlates with structural domains of the protein. Biochemistry 29:9814-9818. (Pubitemid 20348513)
34. Porter TD and Kasper CB (1986) NADPH-cytochrome P-450 oxidoreductase: flavin mononucleotide and flavin adenine dinucleotide domains evolved from different flavoproteins. Biochemistry 25:1682-1687.
35. Sandee D, Morrissey K, Agrawal V, Tam HK, Kramer MA, Tracy TS, Giacomini KM, and Miller WL (2010) Effects of genetic variants of human P450 oxidoreductase on catalysis by CYP2D6 in vitro. Pharmacogenet Genomics 20:677-686.
36. Shimada T, Yamazaki H, Mimura M, Inui Y, and Guengerich FP (1994) Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270:414-423. (Pubitemid 24229655)
37. Stresser DM, Blanchard AP, Turner SD, Erve JC, Dandeneau AA, Miller VP, and Crespi CL (2000) Substrate-dependent modulation of CYP3A4 catalytic activity: analysis of 27 test compounds with four fluorometric substrates. Drug Metab Dispos 28:1440-1448.
38. Venkatakrishnan K, von Moltke LL, Court MH, Harmatz JS, Crespi CL, and Greenblatt DJ (2000) Comparison between cytochrome P450 (CYP) content and relative activity approaches to scaling from cDNA-expressed CYPs to human liver microsomes: ratios of accessory proteins as sources of discrepancies between the approaches. Drug Metab Dispos 28:1493-1504.
39. Vermilion JL and Coon MJ (1978) Identification of the high and low potential flavins of liver microsomal NADPH-cytochrome P-450 reductase. J Biol Chem 253:8812-8819. (Pubitemid 9104669)
40. Wang M, Roberts DL, Paschke R, Shea TM, Masters BS, and Kim JJ (1997) Three-dimensional structure of NADPH-cytochrome P450 reductase: prototype for FMN- and FAD-containing enzymes. Proc Natl Acad Sci USA 94:8411-8416. (Pubitemid 27335052)
41. Xia C, Panda SP, Marohnic CC, Martásek P, Masters BS, and Kim JJ (2011) Structural basis for human NADPH-cytochrome P450 oxidoreductase deficiency. Proc Natl Acad Sci USA 108:13486-13491.